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Abstract
Background: The need for longitudinal, population-based studies to illuminate women’s experiences of symptoms
during the menopausal transition motivated the development of the Seattle Midlife Women’s Health Study.
Methods: Longitudinal, population-based study of symptoms women experienced between the Late Reproductive
stage of reproductive aging and the early postmenopause. Data collection began in 1990 with 508 women ages
35–55 and continued to 2013. Entry criteria included age, at least one period in past 12 months, uterus intact and
at least 1 ovary. Women were studied up to 5 years postmenopause. Data collection included yearly health
questionnaires, health diaries, urinary hormonal assays, menstrual calendars and buccal cell smears.
Results: Contributions of the study included development of a method for staging the menopausal transition;
development of bleeding criteria to differentiate bleeding episodes from intermenstrual bleeding from menstrual
calendars; identification of hormonal changes associated with menopausal transition stages; assessment of the
effects of menopausal transition factors, aging, stress-related factors, health factors, social factors on symptoms,
particularly hot flashes, depressed mood, pain, cognitive, sexual desire, and sleep disruption symptoms, and urinary
incontinence symptoms; identification of naturally occurring clusters of symptoms women experienced during the
menopausal transition and early postmenopause; and assessment of gene polymorphisms associated with events
such as onset of the early and late menopausal transition stages and symptoms.
Conclusions: Over the course of the longitudinal Seattle Midlife Women's Health Study, investigators contributed
to understanding of symptoms women experience during the menopausal transition and early postmenopause as
well as methods of staging reproductive aging.
Keywords: Menopausal transition, Staging reproductive aging, Menopause, Midlife cohort, Symptoms, Endocrine
changes
Background
During the 1970s and 1980s attention to women’s health
research increased in the US, culminating in several im-
portant milestones, among them establishment of the Of-
fice of Women’s Health Research in the National
Institutes of Health in 1991 and development of the first
US Women’s Health Research Agenda [1]. In 1993 the
National Institutes of Health/National Institute on Aging,
National Institute of Child Health and Development, and
collaborating organizations convened a workshop on
Menopause to provide focus for future research about
midlife women and menopause. This work was preceded
by the landmark longitudinal study of the menopausal
transition (MT): the Massachusetts Women’s Health
Study begun in 1982 [2], a longitudinal study developed to
expand knowledge about the experiences of a community-
based population of women as they traversed the MT.
This focus on a community-based population was in
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contrast to earlier studies of clinical populations. Another
early effort by Matthews and colleagues recruited women
from the state of Pennsylvania (The Healthy Women
Study) to determine the natural history of the MT, and be-
havioral and biological changes that occurred during the
MT and postmenopause (PM) and their effects on cardio-
vascular disease risk [3].
The Seattle Midlife Women’s Health Study (SMWHS)
was built on the foundational studies of the 1980s, in-
cluding our longitudinal studies of perimenstrual symp-
toms that focused on women after they had reached age
40 years [4–6]. The SMWHS originated as one compo-
nent of a Center for Women’s Health Research (CWHR)
at the University of Washington School of Nursing in
1989. Funded by the National Institute of Nursing Re-
search, the CWHR was created by an interdisciplinary
cadre of investigators to support research development
in women’s health [7].
Overview of the SMWHS
The initial phase of SMWHS from September 1989 to
July 1996, as part of the CWHR, was designed to test a
model relating MT status, stress exposure, socialization
for midlife, personal and social factors modulating mid-
life experiences, reproductive health history, and health
behaviors to health status and health-seeking behavior in
midlife women between the ages of 35 and 55. A model
including menopausal changes, socialization for midlife,
health status, stressful life context, and vasomotor symp-
toms guided analysis of depressed mood symptoms, an
outcome of interest [8]. The model was generalized to
other symptoms, for example, by testing outcomes in-
cluding hot flashes, sleep, cognitive, mood, and pain
symptoms, to name a few. (The Aims for Phase 1 are in-
cluded in Table 1)
Based on results of the initial study, additional funding
was obtained for the SMWHS from July 1996 to Febru-
ary 2001. This second funding phase focused on the MT
and its relationship to symptoms, altered ovarian func-
tion, perceived stress and stress arousal, as well as symp-
tom management. A major addition to the measures for
this study included hormonal assays (urinary estrone,
FSH, testosterone, cortisol and catecholamines). (Aims
for Phase 2 are included in Table 1).
A third funding phase spanned 2002 through 2006.
Phase 3 of SMWHS continued to focus on symptoms as
the primary endpoints. In addition to linking the symp-
toms to endocrine patterns, the effect of gene polymor-
phisms in estrogen synthesis, metabolism and receptor
genes was added to the aims. (Detailed aims for Phase 3
are given in Table 1).
A fourth and final phase of data collection, after the
end of major funding, continued from 2007 to 2013.
The focus of this phase was to complete the data
collection for the study. Women who had not yet
reached 5 years PM, were not taking any estrogen and
had an intact uterus were entered into this final phase.
Aims for this phase were a combination of the aims
for the three prior phases of funding. The model guid-
ing the longitudinal analysis of symptom data across
all 4 phases is depicted in Fig. 1.
Two small grants supported the fourth phase of the
study. The first was “Menopausal Transition Symptom
Clusters: Genetic, Endocrine, and Social Correlates” that
focused on the secondary analyses of symptom data, par-
ticularly on multiple co-occurring symptoms called
symptom clusters that women experienced during the
MT and early PM. Symptom data were analyzed to iden-
tify clusters of symptoms women experienced and to re-
late them to stress, health behaviors, health status,
endocrine patterns, and gene polymorphisms. (Aims for
this study are in Table 1). A second small grant during
the fourth phase of the study, Urinary Incontinence dur-
ing the Menopausal Transition and Early Postmeno-
pause, was awarded by Pfizer, Inc, Medical Division, that
supported the secondary analysis of urinary incontinence
data over time. (Aims for this study are in Table 1).
In addition, research support was provided by intra-
mural funds to develop a scannable health diary form,
for a pilot study of gene polymorphisms related to symp-
toms, and to complete collection of data from women as
they experienced the early PM (Research Intramural




A prospective, repeated measures design was used to
study a population-based sample of women who were
about to begin or had begun the transition to meno-
pause at the time of entry into the study. Data were col-
lected throughout the study at intervals described below
for a total of 23 years. The study was divided into 4
phases based on the aims associated with each funding
period. Each phase expanded the aims of the previous
phase.
Sample
From early 1990 to early 1992, 508 women were en-
rolled. This original population-based sample from the
Seattle area was obtained by telephone screening of all
households in over 20 census tracts selected for mixed
ethnicity and mixed income. There were 13,120 house-
holds enumerated. Of the 11,222 households able to be
contacted (85.5 % of those enumerated), 1,428 women
between the ages of 35 and 55 were screened (12.7 % of
those contacted) and 820 were eligible (57.4 % of those
screened). In addition to age, a woman was eligible if
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she had an intact uterus and at least one ovary, had at
least one menstrual period within the past 12 months,
was not pregnant or lactating, and could read and
understand English. Of the 820 women eligible, 620
agreed to participate (75.6 % of those eligible) and 508
actually began the study and provided initial cross–
Table 1 Aims for the Seattle Midlife Women’s Health Study by
Phase
Phase 1: 1990–1996
The aim of Phase I was to test a model relating menopausal status,
stress exposure, socialization for midlife, personal and social factors
modulating midlife experiences, reproductive health history, and health
behaviors to health status and health-seeking behavior in midlife
women between the ages of 35 and 55.
Phase 2: 1996–2001
Aim 1. Describe the progression through stages of the
perimenopuse (pre transition, early transition, middle transition, late
transition, and postmenopause as determined from annual health
updates and daily menstrual calendars) for women over a nine year
period with respect to:
a) Symptoms, including vasomotor, dysphoric mood, insomnia,
somatic, and discomfort symptoms, recorded in a daily health diary
for three days monthly (coinciding with hormone assays);
b) Altered ovarian function (estrone, testosterone (T), and FSH),
measured in first morning urine samples at monthly intervals;
c) perceived stress (stressful life events, income inadequacy)
measured annually and perceived stress measured 3 days each
month in the health diary;
d) stress arousal (urinary levels of cortisol and catecholamines)
measured in the first morning urine samples at monthly intervals;
and
e) symptom management, including use of health services and
hormone replacement therapy assessed annually in a health update
questionnaire and interview.
Aim 2. Test the following hypotheses regarding symptoms during
the three stages of the transition to menopause (early to middle to late):
a) women who experience more severe vasomotor symptoms
during the transition to menopause will have: higher levels of
perceived stress, lower levels of estrone, and higher levels of
catecholamines and cortisol;
b) women who experience more severe dysphoric mood
symptoms during the transition to menopause will have: higher
levels of perceived stress, higher levels of cortisol, and
norepinepherine, and a lower estrogen:androgen ratio;
c) women who experience more sever insomnia symptoms during
the transition to menopause will have: higher levels of perceived
stress, lower levels of estrone, and higher levels of catecholamines.
Aim 3. Test the relationship within individual women among HPO axis
hormones (estrone, FSH, testosterone), indicators of physiologic stress
arousal (cortisol and catecholamines), daily stress ratings, and symptoms
(especially vasomotor, dysphoric mood, and insomnia), measured
monthly over a nine year period, using auto-correlation and cross-
correlation techniques.
Aim 4. To estimate the stability of symptom patterns women have
recorded in daily health diaries each year with symptom patterns
women experience during the menopausal transition (over the period
of 1991 to 1995, 1996–2000 and 2001–2005).
Phase 3: 2002–2006
Aim 1. Describe and compare women in the menopausal transition
(early, middle and late transition), in the early postmenopause, and
those who use HRT, on indicators of pituitary-ovarian hormone changes,
perceived stress, physiologic stress arousal, vasomotor, dysphoric mood,
somatic, discomfort and insomnia symptoms.
Aim 1 Hypotheses:
Hypothesis 1: Women in late transition will have higher levels of urinary
FSH, cortisol and norepinepherine, higher perceived stress
and higher vasomotor symptom severity than women in
early or middle transition.
Hypothesis 2: Women in the postmenopause will have lower levels of
urinary estrone and testosterone, lower perceived stress
and higher levels of FSH and vasomotor symptoms than
women in the three menopausal transition stages.
Hypothesis 3: There will be no group differences among women in the
three menopausal transition stages for urinary estrone,
Table 1 Aims for the Seattle Midlife Women’s Health Study by
Phase (Continued)
testosterone and epinephrine, depressed mood or the 5
symptom clusters except for vasomotor symptoms.
Hypothesis 4: Women on HRT will have higher estrone levels and lower
perceived stress, urinary cortisol, and vasomotor
symptoms than women who are not on HRT, those in the
menopausal transition or those who are postmenopausal.
Aim 2. Compare women in the menopausal transition and early
postmenopause with different estrogen metabolism and catabolism gene
polymorphisms with respect to estradiol and estrone levels, age of onset
of middle and late menopausal transition stage and menopause, and
heaviness of menstrual blood flow.
Aim 3. Compare women in the menopausal transition and early
postmenopause with different estrogen receptor gene polymorphisms
with respect to estradiol and estrone levels, age of onset of middle and
late menopausal transition stage and menopause, and heaviness of
menstrual blood flow.
Phase 4: 2007–2013
Continuation of aims from Phases 1 –3.
Additional aims for the Symptom Cluster Study that was part of Phase 4.
1. Identify symptom clusters (SC) SMWHS participants experienced
during the late reproductive, early menopausal transition stages and
early postmenopause using latent class analysis to complement the
preliminary analyses of the late stage SCs;
2. Determine the consistency of SCs with the clusters identified for the
late menopausal transition stage across the late reproductive stage,
early menopausal transition stage and early postmenopause;
3. Test models hypothesizing the relationship between SC groups and
profiles of:
a) gene polymorphisms in the estrogen synthesis pathways (CYP 19
and 17 HSD) and genes polymorphisms in neuroendocrine
pathways modulated by estrogen (5HTTLPR, NPY, BDNF);
b) hypothalamic-pituitary-ovarian (HPO) biomarkers (E, T, FSH), and
hypothalamic-pituitary-adrenal (HPA – cortisol) and autonomic ner-
vous system (ANS- epinephrine, norepinephrine) biomarkers;
c) reproductive aging stages (late reproductive, early and late
menopausal transition, and early postmenopause);
d) socio-behavioral risk factors (e.g. high stress, role burden, low
income adequacy, employment, education, social support);
e) symptom vulnerability factors (e.g. history of sexual abuse, low
mastery, self-consciousness, low self esteem); and outcomes of
well-being and interference with work and relationships;
4. Based on a systematic review of controlled clinical trials for
managing hot flashes, identify treatment effects on co-occuring
symptoms and reported adverse treatment effects, including sleep
disturbances, mood, pain and cognitive symptoms;
5. Synthesize results of the empirical analyses (aims 1–3) and
systematic review (aim 4) to develop novel symptom cluster
management protocols to be tested in a future feasibility study.
Additional aims for Urinary Incontinence Study that was part of Phase 4.
1. Determine the influence of age and menopausal transition factors
on the experience of urinary incontinence (stress, urge and any
incontinence) among midlife women;
2. Assess the influence of lifespan health factors and life context
(personal and social resources and stress) on urinary incontinence;
and
3. Determine the relationship between urinary incontinence and well-
being, symptoms (fatigue, disrupted sleep, anxiety and depressed
mood) and interference with daily living (work and relationships).
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sectional data (81.9 % of those who initially agreed to
participate) (See Table 2). 390 of the 508 women entered
the longitudinal component of the study (76.8 % of the
cross-sectional sample) by agreeing to provide data over
time. A description of the characteristics of the women
who agreed to participate in the longitudinal component
(N= 390) and those who only completed the initial cross
sectional component (N= 118) is shown in Table 3.
Those who entered the longitudinal component com-
pared to those who did not enter were more likely to be
partnered, not a parent and not Black. There were no
significant differences for education, employment, age,
BMI, income and stress level.
For entry into the second major funding phase of the
study (mid-1996), women still enrolled at the end of the
previous phase of this longitudinal project, plus those who
had dropped out of phase 1 but had contributed at least
two years of data, were contacted by phone about partici-
pating in this second phase. A total of 300 women were
contacted in mid-1996 and screened for continuing eligibil-
ity (5 years or less PM or, if taking hormones, age less than
60 years old, uterus intact and at least one ovary intact). Of
those 300 women screened, 243 were eligible and agreed to
enroll in phase 2 (62 % of the 390 who began the longitu-
dinal component). In addition, between 2000 and 2002, 174
women provided a buccal cell smear for genotyping. See
Fig. 2 for retention across the entire project.
For entry into the third major funding phase of the
study (2001–2006) all eligible women (5 years or less
PM or, if taking hormones, age less than 60, uterus
intact and at least one ovary) who were still partici-
pating (N = 160) were contacted and screened (66 %
of those who entered phase 2). Of these 160 women,
144 (90 %) agreed to continue for a third phase. At
the end of phase three 67 women were still eligible
and participating.
Research funds from the UW School of Nursing Research
Intramural Funding Program were obtained in 2007 to con-
tinue data collection from those still eligible for the study.
Of these 67 women, 64 were eligible and agreed to continue
participation in the fourth and final phase until no longer
eligible. This part of the study continued until February
2013 when all data collection was completed. Of the ori-
ginal 508 women who entered the study, by the end of the
study in 2013, 173 had dropped due to personal reasons
(34 %), 162 were lost to contact (32 %) and 173 became in-
eligible sometime during the study (34 %).
Retention efforts
Numerous efforts were taken to retain the eligible sam-
ple throughout the study. These include the following:
 yearly birthday card with a personal note
 yearly thank you checks through the first two
funding periods
Fig. 1 General Model Guiding SMWHS Symptom Analyses Across Time
Table 2 Smwhs sample identification and screening
Sampling Identification N and (% of total enumerated)
Households enumerated 13,120 (100 %)
Households contacted by phone 11,222 (86 %)
Women in households 35–55 years
of age screened
1,428 (11 %)
Women eligible after screening 820 (6 %)
Women who agreed to participate 620 (5 %)
Women who actually began study 508 (4 %)
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 personal and consistent contact by the research staff
– reminder postcards about data collection
– in-person pick-up of urine and diaries at a com-
munity site or at home
– reminder phone calls about pick-up of data
 flexibility regarding schedules; negotiating
alternatives
 periodic sharing of findings with women
 yearly newsletter, The Midlife Times
 two Health Fairs at community sites
 a web site
 a certification of appreciation after 10 years of
participation
 easy access to research staff via phone and email
Data collection
In the first phase of the study all measures were pencil
and paper measures. This included measures of symp-
tom severity, stress, personal and social resources,
socialization for midlife and aging, reproductive health
experiences including menstrual cycle changes, social
environmental demands, and personal health practices.
These measures were obtained in an annual daily health
diary across two to three menstrual cycles, an annual
health questionnaire and a menstrual calendar.
In the second phase of the study measures of pituitary-
ovarian and pituitary-adrenal function were added. These
additional measures were obtained by collecting monthly
first AM urine specimens on day 6 of the menstrual cycle,
if the woman was still cycling. Women were instructed
not to eat, drink, smoke, take medications or exercise be-
fore each urine collection. The health diary was collected
on 3 consecutive days (days 5, 6 and 7) to coordinate with
the time of the urine collection (day 6). For those with
very erratic bleeding and those no longer having periods a
consistent 3 days of the month was used for data collec-
tion. This procedure was used from late 1996 through
2000.
The data collection time for the diary and urine speci-
mens was modified from 2001 through 2005. The timing
was changed from monthly to quarterly for both the
diary and urine collections. During all phases of the
study the yearly health questionnaire and menstrual cal-
endars were continued (See Table 4 for sample size for
each measure by year).
In addition, buccal cell smears were obtained from 174
of these women between 2000 and 2002. Urine collections
stopped at the end of 2005. From 2006 to the end of the
study quarterly health diaries, yearly health questionnaires
and menstrual calendars, if still bleeding, were obtained.
Table 3 Baseline Sample Characteristics for women who participated in the Longitudinal Component Compared with women who
participated only in the Cross Sectional Component (1990–1991)
Women in Longitudinal Component
(n = 390)
Women in Cross Sectional Component
(n = 118)
Characteristic Mean (SD) Mean (SD) p value*
Age (years) 41.5 (4.3) 41.4 (4.4) 0.43
Years of education 15.7 (2.8) 15.3 (3.2) 0.15
Family gross income ($) 37360 (15,800) 35,500 (17,460) 0.27
Number live births 1.97 (1.4) 1.57 (1.4) .006
Perceived stress 2.2 (0.55) 2.3 (0.55) 0.31
Characteristic N (Percent) N (Percent) p value**
Currently employed
Yes 336 (86.1) 102 (86.4) 0.94
No 54 (13.8) 16 (13.6)
Race/ethnicity
African American 32 (8.2) 26 (22.0) .001
Asian /Pacific Islander 34 (8.7) 9 (7.6)
Caucasian 311 (79.7) 80 (67.8)
Other (Hispanic, Mixed) 13 (3.3) 3 (2.5)
Marital Status
Married/partnered 277 (71.0) 71 (60.2) 0.03
Never partnered/ divorced/widowed 113 (29.0) 47 (39.8)
Never married/partnered 21 (7.2) 14 (6.5)
*Independent t-test
**Chi-square test
Woods and Mitchell Women's Midlife Health  (2016) 2:6 Page 5 of 16
Data handling
Except for the interview at the start of the study, all data
in phase 1 and phase 4 were collected by mail (yearly
questionnaire, diaries, menstrual calendars). In phases 2
and 3 the diaries and urine samples were collected in
person while the annual questionnaire and menstrual
calendar were collected by mail. For the urine samples,
after the first morning urine was collected by the partici-
pant it was immediately frozen in a home freezer at 0°.
These specimens were either brought frozen to a com-
munity site by the participant at a prearranged time or
were picked up by a research associate within 56 days
(8 weeks) of collection. Each specimen was kept frozen
during transport and then taken to the University of
Washington School of Nursing Biobehavioral Lab and
placed in a −70° centigrade freezer. The specimens were
then assayed by the laboratory staff. (See Additional
file 1: Assay Descriptions and Laboratory Assay Proced-
ure). A maximum of 56 days for home freezing was deter-
mined by the laboratory staff using various intervals and
testing for sample degradation. The diaries were picked
up in a similar manner as the urine during phases 2 and 3.
If urine was not collected, the diaries were mailed to the
study personnel.
Fig. 2 Retention Flow Chart. *Funding phases
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Measures
A blank menstrual calendar was mailed at the end of
each calendar year for completion during the following
year. Any occurrence of bleeding (B) or spotting (S) was
recorded. Beginning in 1996, the amount of B on a scale
of 1 (light flow) to 4 (very heavy/flooding) was recorded
with each occurrence. Spotting was any bloody vaginal
discharge that did not require any protection [9]. (See
Additional file 1 for sample calendar). The menstrual
calendars were returned at the start of the following year
and reviewed for completeness.
Definitions of bleeding events used for the study,
called standard bleeding events, were modifications of
those recommended by WHO [9] [Gray, RH. WHO
Meeting on the Analysis of Bleeding Patterns, Feb 28,
1978, unpublished]. A standard bleeding episode was de-
fined as ≥2 days of B or a mix of ≥2 B and S days but
not all S days with ≤2 bleed free days. A standard bleed-
ing interval was any series of ≥4 consecutive bleed-free
days bounded by bleeding episodes. A bleeding segment
was a bleeding episode and the subsequent bleeding
interval.
The WHO standard definitions did not differentiate
bleeding episodes from intermenstrual bleeding (IMB)
or non-menses bleeding such as S or B days between
consecutive bleeding episodes and within a bleeding
interval. A limitation of the WHO standard definition of
a bleeding episode (≥1 days B or S) was the creation of
many very short bleeding segments. Short bleeding seg-
ments can overstate the incidence of irregularity, bias
downward the age of onset of each MT stage and bias
upward the duration of MT stages. To address this prob-
lem of short bleeding segments additional criteria were
developed by the study staff and Sybil Crawford, PhD, to
determine if a bleeding event with 1 B day or 1 or more
S days only was an episode or IMB and whether 3 bleed
free days between B or S days represented a bleeding
interval or was part of the episode. The criteria were ap-
plied using the woman as the unit of analysis as recom-
mended by Treloar [10] (See Additional file 1 for
Nonstandard Bleeding Criteria). The basic premise be-
hind these additional criteria was that the typical bleed-
ing pattern of some women can reflect a slight variation
from the standard definitions and that IMB or non-
menses bleeding is a phenomenon that needs to be
accounted for as part of a woman’s bleeding pattern.
A reduction in the number of short bleeding segments
was the result of this procedure. In the SMWHS sample.
The majority of instances of 1 S day or ≥2 S days to-
gether occurred between episodes, in the bleeding inter-
val (unpublished data).
After all the bleeding criteria were applied to the cal-
endar data each calendar was assigned a subgroup for
staging using staging criteria developed by the study
personnel [11] and modified based on the findings of the
ReSTAGE Collaboration [12] (See Additional file 1 for
Staging Criteria).
A health questionnaire was mailed at the end of each
year. This questionnaire obtained data about changes in
health, the menstrual cycle, current health practices,
medication use, stress, social support, mental health,
symptoms and well-being. (See Additional file 1 for a
summary of measures included in the annual health
questionnaires).
A health diary was kept by a subset of the original
508 women. Initially this diary was kept daily for two to
three menstrual cycles. It was completed once a year for
three years (at the start of the study, 12 months later,
and 24 months from the start). The data from this early
diary was hand entered into the computer. In 1994 the
diary was converted to a scannable format and for 1995
and 1996 was kept daily for two weeks once a year
(around the time of the yearly health questionnaire). Be-
ginning in late 1996 to the end of 2000 this scannable
diary was kept for 3 days every menstrual cycle on days
5, 6, and 7, if there were identifiable menstrual periods,
to correspond with the urine collection on day 6. Other-
wise it was kept monthly on the same 3 days every







1990–1992 508 367 NA
1993 347 259 NA
1994 309 261 NA
1995 250 141 NA
1996 192 146 NA
1997 233 176 170 (1783)
1998 205 162 167 (1820)
1999 212 149 157 (1478)
2000 190 103 106 (1036)
2001 175 79 85 (340)
2002 157 65 74 (279)
2003 140 59 59 (236)
2004 110 46 54 (208)
2005 95 44 49 (179)
2006 84 30 NA
2007 57 20 NA
2008 47 18 NA
2009 37 15 NA
2010 31 10 NA
2011 20 10 NA
2012 17 5 NA
2013 12 5 NA
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month. Starting in 2001 the diary was completed once a
quarter for the same 3 consecutive days instead of
monthly. The diary included items such as symptoms
commonly experienced by midlife women, medication
use, stress levels and health practices (smoking, drinking
alcohol, caffeine use, exercise, sleep). (See Additional file
1 for sample pages of the diary).
Urine specimens were obtained from a subset of
women one time per menstrual cycle on day 6 or once a
month if there were no identifiable periods. These urine
collections began in late 1996 and continued until the end
of 2005. This was a first morning specimen and was
assayed for estrone glucuronide, FSH, total testosterone,
cortisol, epinephrine and norepinephrine. (See Additional
file 1 for assay descriptions).
A buccal cell smear was obtained for genetic analysis
from 174 women sometime between 2000 and 2002. (See
Additional file 1 for buccal cell smear collection procedure
and Additional file 1 for genotyping sequencing).
Analytic strategies
A variety of analytic strategies was used over the course
of the study. Examples include discriminant function
analysis [9], confirmatory factor analysis and LISREL [8–
14], content analysis with cross tabulations [15–17],
ANOVA and regression analysis [18], cluster analysis
[19], t-tests [20], time series analysis [21], general esti-
mating equation [22] and numerous papers since 2006
using multilevel modeling (MLM) [23–35]. The analytic
method called multi-level modeling (MLM) was used for
most of the longitudinal analyses once most of the data
were collected and processed (from 2006 on). For all
MLM analyses age was used as the measure of time.
This method was specifically adapted for the SMWHS
data by a statistician (Don Percival, PhD) and was devel-
oped using an R program to account for specific charac-
teristics of the data such as an unbalanced design, serial
correlation, and missing data [30]. (See Additional file 1
for a detailed description of the MLM procedure).
Results
Selected results are presented to illustrate the contribu-
tions of each phase of the SMWHS. A complete list of
publications from the Seattle Midlife Women’s Health
Study is appended to the References section.
Phase 1
Data collected during phase I of the study were used to
amplify our understanding of women’s views of midlife
and menopause, as well as to evaluate models of
women’s health and health-seeking behavior during mid-
life. In response to open-ended questions, women de-
scribed midlife as a time of many transitions: getting
older and changing bodies, outlooks and relationships.
Personal achievements and employment were central to
the lives of midlife women in this study [16]. Women
viewed menopause as a period of transition. When
women were asked about their anticipation of meno-
pause they indicated it was a time of uncertainty that
elicited mixed feelings [17]. Women also revealed their
meanings of menopause as the cessation of periods, ex-
periencing the end of fertility and reproductive capacity,
hormonal changes, new or different life stage, changing
emotions, changing bodies, symptoms, and part of the
aging process. Few referred to menopause as a time of
risk for disease or of need for health care.
A model of depressed mood symptoms was developed,
evaluating 3 pathways to depressed mood, comparing
the influence of the MT, stressful life context, and health
status pathways in a multiethnic sample (N= 337). The
stressful life context pathway was most influential in ac-
counting for depressed mood. Health status had a direct
effect on depressed mood and an indirect effect through
perceived stress. The menopausal changes pathway had
little explanatory power. At the time this model was
tested, the majority of participants were in the Late Re-
productive stage or the Early MT stage. Nonetheless,
these results suggested the need for clinicians to look
beyond menopausal status to the broader context of
midlife women’s lives [8].
The primary endpoint throughout the study was type
and severity of symptoms women experienced and re-
ported during the MT and early PM. When the symp-
toms women experienced during midlife were first
examined, measured during the premenses week, several
groups were identified, including: dysphoric mood, vaso-
motor, somatic, neuromuscular,and insomnia symptoms.
Notably the stability of vasomotor and somatic symp-
toms was lowest over the three year period studied, but
dysphoric mood, neuromuscular, and insomnia symptoms
were relatively stable, suggesting their chronic experience
in this cohort [13]. The variability of the vasomotor and
somatic symptoms over the three year period led to a
focus on the role of the MTand related hormonal changes
during subsequent phases of the study.
During phase 1 women’s health-seeking behavior was
also investigated and was then tracked during subse-
quent phases. After publication of Women’s Health Ini-
tiative findings in 2002 linking hormone therapy (HT)
with increased risk of breast cancer, stroke, heart attacks
and other health problems, the percent of women taking
hormones during the MT decreased from 49 % in 1999
to 35 % in 2003 [23].
Phases 2, 3, and 4
Development of a staging system
Phase 2 of the study focused on the development of a
staging system for the MT that eventually informed and
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was integrated with the Staging Reproductive Aging
Workshop (STRAW) efforts [36], and later validated by
the multi-country work of the Re-STAGE Collaboration
[11, 37–39]. Mitchell led development of the MT staging
system from detailed observation and analysis of men-
strual calendar data over a seven year period (1990–
1997) [11]. Development of the staging system for the
MT provided a useful framework to organize subsequent
analyses and demonstrate the influence of the MT stages
on endocrine patterns, symptoms, and other aspects of
the MT.
An important measurement issue related to staging re-
productive aging was whether retrospective and pro-
spective reporting of menstrual irregularity by women
would influence staging efforts. Agreement between
women’s reporting on a menstrual calendar and ques-
tionnaires with retrospective reports was weak, thus we
incorporated only prospective reporting on menstrual
calendars in the SMWHS staging approach [40].
The original and modified stages and criteria for sta-
ging used by SMWHS were as follows:
Pretransition stage when cycles were regular with no
change in length of periods, amount of flow or cycle
length from the previous year. This stage was later called
Late Reproductive stage to correspond to STRAW
recommendations.
Early stage when cycles were still regular but there was
a change in length of periods, amount of flow or cycle
length from the previous year. This stage was later called
Late Reproductive stage to correspond to STRAW
recommendations.
Middle stage when cycles became irregular, i.e., start of
consecutive cycles were 7 or more days apart. This stage
was later called Early stage to correspond to STRAW
recommendations.
Late stage when periods were skipped, i.e., twice the
modal cycle length between consecutive cycles. The cri-
teria for this stage were later changed to 60 or more days
of amenorrhea between the start of consecutive periods
to correspond to the findings from the ReSTAGE Col-
laboration [39].
The original focus of staging in the SMWHS was on the
menopausal transition. When the Staging Reproductive
Aging Workshop (STRAW) investigators proposed use of
stages of reproductive aging across the lifespan, we adopted
the STRAW staging approach derived from consensus of
investigators who participated in the STRAW workship in
2001. Our initial staging system had included an early, mid-
dle, and late stage of the menopausal transition. Because
the STRAW investigators believed that the menopausal
transition did not begin until cycle intervals became irregu-
lar, we adapted our staging to fit their recommendations.
We no longer used our old definition of early menopausal
transition, which included regular cycles with more subtle
changes in the length of the period and cycle length, and
instead adopted the STRAW definition of early stage. We
also changed our pretransition stage to use the nomencla-
ture of STRAW: late reproductive stage.
Age of onset of MT stages and the final menstrual
period (FMP), and duration of the Early and Late MT
stages were identified. On average, women (N= 121) en-
tered Early stage at age 46.4 (SD = 3.4) and stayed in the
stage (N= 82) for an average of 2.8 years (SD = 1.5). On
average, women (N= 130) entered Late stage at age 49.4
(SD = 2.7) and stayed in this stage (N = 84) for an aver-
age of 2.5 years (SD = 1.3). The average age (N = 114) for
the FMP (start of PM) for this cohort was 52.1 (SD =
2.9) years [37].
To identify an onset of each MT stage it was neces-
sary to have bleeding data about the prior stage for the
previous 12 months so the time of change could be
identified. For example, using the staging criteria, if a
woman was in Early stage for one year and the next
year met the criteria for Late stage, the onset of Late
stage could be identified. However, if she was in Late
stage for one year but the prior 12 months of calendar
data were not available, her onset of Late stage would
be unknown. This same situation also would apply to
onset of Early stage. Content analysis of women’s de-
scriptions of irregularity and skipping of periods re-
vealed that using simple questions about these was not
adequate to apply the staging criteria. Instead, it was
important to use the menstrual calendars to collect ac-
tual bleeding data [40].
Hormonal changes across the menopausal transition
An inspection of changes in urinary FSH (follicle-stimu-
lating hormone) levels across the MT showed a rise as
women progressed from Early MT to Late MT stage and
to early PM and urinary estrone levels rose slightly from
the Early to the Late MT stage and then dropped sub-
stantially the final year before and the first year after the
FMP. Urinary testosterone levels remained flat across
all MT stages and early PM. When these 3 hormones
were analyzed for an association with MT stage across
time, early PM had a significant negative effect on es-
trone and both Late MT stage and early PM had a sig-
nificant positive effect on FSH. Testosterone was not
affected by stage (unpublished data). (See Figs. 3 a,b,c)
When these same hormone levels were graphed based
on number of years before and after FMP (from 8 years
before to 5 years after FMP) FSH began to rise at 3 years
before FMP and steadily increased to 3 years after FMP
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when it leveled off to at least 5 years FMP. Estrone
showed a drop in level within 1 year before FMP and
then slowly continued to decline to at least 5 years after
FMP. Testosterone began to rise within 1 year before
FMP, peaked at 3 year after FMP and declined steadily
to at least 5 years after FMP (See Figs. 3 d,e,f ).
Because of the important relationship of stress during
midlife to symptoms, urinary cortisol was studied. The
findings showed an increase in cortisol in the 7 to
12 months after onset of Late stage compared to the 7
to 12 months before onset of Late stage [20]. Also,
women with increased cortisol levels during the Late
stage had more severe hot flashes than those without a
cortisol increase during the same stage [20]. In another
study of cortisol using multilevel modeling there was a
significant positive relationship between urinary epi-
nephrine, norepinephrine, estrone, FSH, testosterone
and hot flashes with cortisol levels in a univariate model.
Health-related and social factors and symptoms other
than hot flashes did not show a significant effect on cor-
tisol levels. When the significant variables were com-
bined in a multivariate model only estrone and FSH had
a significant effect on cortisol [25].
An inspection of changes in urinary cortisol revealed a
rise in the late MT stage, as seen in earlier analyses (See
Fig. 4a) [15] and inspection revealed a gradual increase
from 7 years before to 5 years after FMP (Fig. 4b). An in-
spection of urinary epinephrine and norepinephrine levels
across MT stages showed a minimal change in epineph-
rine across stages and a slight rise in norepinephrine from
Early MT stage to early PM (Fig. 4 c and d). When a
multilevel analysis of these catecholamines across MT
stage was done no significant effect of stage was found on
epinephrine or on norepinephrine (unpublished data). In
contrast, when number of years before and after FMP
were examined, epinephrine showed no definitive pattern
while norepinephrine slowly rose from 8 years before
FMP to 5 years after FMP (Fig. 4 e and f).
Well-being and the menopausal transition
General well-being as measured by the 4 item subscale
of the General Well-Being Scale [41] was positively asso-
ciated with satisfaction with social support and a sense
of mastery [27]. A decrease in well-being was associated
with negative life events. Being in Late Stage of MT was
associated with a decrease in well-being only in the uni-
variate analysis.
Symptom patterns across the menopausal transition
Because the primary end points throughout the SMWHS
were symptoms, of interest was identifying effects of MT
stages on various types of symptoms. In addition, we
used a general model (See Fig. 1) to guide analyses of
women’s symptom experiences over time that included
the following concepts and examples of indicators for
each: menopausal transition factors, aging, health-related
factors, stress-related factors, and other co-occurring
symptoms. In the following paragraphs, findings related
to each of the symptom groups studied are summarized.
Fig. 3 Endocrine Values Across Menopausal Transition Stages and Years Before and After the Final Menstrual Period (FMP). a. Urinary estrone across
menopausal transition stages; 3b. Urinary Estrone Level before and after FMP; 3c. Urinary FSH across menopausal transition stages; 3d. Urinary FSH
Level before and after FMP; 3e. Urinary Testosterone across menopausal transition stages; 3 f. Urinary Testosterone Level before and after FMP
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Hot flashes
An analysis of women using and not using hormone
therapy (HT) revealed that increases in hot flash severity
were associated with late transition stage, early postmen-
opause, use of HT, duration of early transition stage, age
of entry into early PM and level of FSH. Age of entry
into early transition and estrone levels were associated
with decreased hot flash severity. Not associated with
hot flash severity were being in early transition stage,
age of entry into or duration of late transition stage and
all of the psychosocial (anxiety, stress, depressed mood)
and lifestyle variables (BMI, activity level, sleep, alcohol
use). Use of HT ameliorated but did not eliminate severe
hot flashes [23].
Hot flash severity persisted through the MT stages,
peaking in the Late MT stage and diminishing only after
the second year PM. Hot flash severity was associated
with being older, being in the Late MT stage or early
PM, beginning the Late MT stage at a younger age and
reporting greater anxiety. In a model including only
endocrine factors, hot flash severity was significantly as-
sociated with higher FSH and lower estrone levels [34].
Sleep symptoms
Severity of nighttime awakening was significantly asso-
ciated with age, Late MT stage and early PM, higher
FSH, lower E1G, more severe hot flashes, depressed
mood, anxiety, joint pain, backache, and perceived stress,
history of sexual abuse, poorer perceived health, and less
alcohol use [30]. Severity of problems going to sleep
was associated with hot flashes, depressed mood,
anxiety, joint pain, backache, perceived stress, history of
sexual abuse, poorer perceived health, less alcohol use,
and lower cortisol, but not with MT stages or hormone
levels. Severity of early morning awakening was signifi-
cantly associated with age, hot flashes, depressed mood
anxiety, joint pain, backache, perceived stress, history of
sexual abuse, poorer perceived health, but not MT
stages, estrone, or FSH.
Depressed mood
Most women experienced the MT without a high level of
depressed mood. A small group of women experienced
worsening of their mood. Another small group experi-
enced improvement in their mood [19]. Women with con-
sistently depressed mood were more likely to have hot
flashes, stress, history of premenstrual syndrome and post-
partum blues than women with occasional depressed
mood or those without depressed mood [19, 42].
Depressed mood symptoms (measured by CES-D
scores) were associated with being in the Late MT stage,
severity of hot flashes, life stress, family history of depres-
sion, history of postpartum blues, sexual abuse history,
body mass index, and use of antidepressants. Hormonal
levels and age of entry into and duration of Late MT stage
were unrelated [24]. In another multivariate analysis,
when covariates were examined individually, a decrease in
depressed mood as a single symptom was associated with
early PM, higher estrone, more exercise and being part-
nered. An increase in depressed mood was associated with
perceived stress, a history of sexual abuse and more severe
sleep disruption symptoms (problem getting to sleep,
Fig. 4 a. Urinary Cortisol by Menopausal Transition Stage. b. Urinary Cortisol by Years Before and After FMP. c. Urinary Epinephrine by
Menopausal Transition Stages. d. Urinary Norepinephrine by Menopausal Transition Stages. e. Urinary Epinephrine by years Before and After FMP.
f. Urinary Norepinephrine by Years Before and After FMP
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awakening at night, early morning awakening). FSH level,
BMI, alcohol use, number of live births and hot flash se-
verity were not associated with depressed mood. In a
model with multiple covariates that individually had a sig-
nificant effect, awakening at night no longer significantly
increased depressed mood. Also, estrone level and early
PM were no longer associated with a decrease in de-
pressed mood [Mitchell, ES and Woods, NF Depressed
Mood during the Menopausal Transition, Reproductive
Aging and Life: Observations from the Seattle Midlife
Women’s Health Study. Unpublished].
Cognitive symptoms
Women in the Late Reproductive and Early MT stages
and those who used hormones reported more problems
with memory measured by the Memory Functioning
Questionnaire than women in Late stage [18]. About
72 % of women reported problems remembering names
at least some of the time. About 50 % had a problem re-
membering where they put things, recent phone num-
bers, things others told them (or they told others),
keeping up correspondence and forgetting what they
were doing. However, none of these events was consid-
ered a serious problem [18]. Many types of problems
with memory were related to lower ratings of health and
depressed mood. Problems with current memory and re-
membering past events were associated with higher
levels of reported stress, which women attributed to the
burden of meeting multiple role demands [18].
Memory changes most noted by women (mean age
47 years) who responded to open-ended questions about
their memory were difficulty remembering words or num-
bers, i.e., verbal memory. These changes were attributed
to increased role burden and stress, getting older, physical
health, menstrual cycle changes/hormones, inadequate
concentration, and emotional factors [15].
As individual covariates and in a multivariate model,
age, anxiety, depressed mood, night-time awakening,
perceived stress, perceived health, and employment were
each significantly related to difficulty concentrating.
Hot flashes, amount of exercise and history of sexual
abuse had a significant effect as individual covariates but
not in the final multivariate model. The best predictors
of forgetfulness when analyzed as individual covariates
and in the multivariate model were age, hot flashes, anx-
iety, depressed mood, perceived stress, perceived health
and history of sexual abuse [32].
Pain symptoms
Pain symptoms rose slightly with age. A significant in-
crease in back pain was reported during the Early and
Late MT stages and early PM, but urinary E1G, FSH and
testosterone levels were unrelated. Of the stress-related
factors, perceived stress and lower overnight urinary
cortisol levels were associated with more severe back
pain; history of sexual abuse and catecholamines did not
have a significant effect. Women most troubled by
symptoms of hot flashes, depressed mood, anxiety,
night-time awakening, and difficulty concentrating re-
ported significantly greater back pain. Of the health-
related factors, having worse perceived health, exercising
more, using analgesics, and having a higher body mass
index were associated with more back pain, but alcohol
use and smoking did not have significant effects. Of the
social factors, only having more years of formal educa-
tion was associated with less back pain; parenting, hav-
ing a partner, and employment did not have significant.
Factors associated with joint pain included age but not
menopausal transition-related factors. Symptoms of hot
flashes, night-time awakening, depressed mood, and dif-
ficulty concentrating were each significantly associated
with joint pain. Poorer perceived health, more exercise,
higher body mass index, and greater analgesic use were
all associated positively with joint pain. History of sexual
abuse was the only stress-related factor significantly re-
lated to joint pain severity [29].
Sexual desire symptoms
Women’s concerns about decreasing sexual desire dur-
ing midlife prompted analysis of factors influencing sex-
ual desire as recorded in the symptom diaries. Women
reported a significant reduction in sexual desire during
the Late MT stage and early PM. Those with higher
urinary E1G and T reported significantly higher levels of
sexual desire whereas those with higher FSH levels re-
ported significantly lower sexual desire. Women using
hormone therapy also reported higher sexual desire.
Those reporting higher perceived stress reported lower
sexual desire, but having a history of sexual abuse did
not have a significant effect. Those most troubled by
symptoms of hot flashes, fatigue, depressed mood, anx-
iety, difficulty getting to sleep, early morning awakening,
and awakening during the night also reported signifi-
cantly lower sexual desire, but there was no effect of va-
ginal dryness. Women with better perceived health and
those reporting more exercise and more alcohol intake
also reported greater sexual desire. Having a partner was
associated with lower sexual desire [26].
Urinary incontinence symptoms
Stress urinary incontinence (SUI) was associated sig-
nificantly with individual predictors of worse perceived
health, history of ≥3 live births, being in the Early MT
stage, having less formal education and being white.
Urge incontinence (UUI) was associated significantly
with individual predictors of increasing age, worse per-
ceived health, BMI ≥30, history of ≥3 live births, and lower
FSH levels. Both SUI and UUI were significantly associated
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with lower self-esteem and with age included in the models
as a measure of time. UI effects on mood symptoms, atti-
tudes toward aging and menopause, perceived health and
consequences for daily life were not significant [22, 33].
Interference of symptoms with work and relationships
Women reported the effects of their symptoms on work
and relationships in the symptom diary. Analyses of the
extent to which symptoms interfered with daily living re-
vealed that interference with work was significantly as-
sociated with perceived health, stress, hot flashes,
depressed mood, anxiety, difficulty getting to sleep,
awakening during the night, early morning awakening,
backache, joint pain, forgetfulness and difficulty concen-
trating. Interference with relationships was signifi-
cantly associated with age and individual covariates
perceived health, estrone, perceived stress, depressed
mood, anxiety, sleep symptoms, backache, joint pain,
forgetfulness and difficulty concentrating [31].
Genetic influences and the menopausal transition
Polymorphisms in the estrogen synthesizing, metaboliz-
ing, and receptor genes were genotyped and associated
with both symptoms and the timing of the events of the
MT. Women with the CYP19 11r polymorphism reported
more severe and frequent hot flashes during the Early and
Late MT stages and early PM and higher E1G levels dur-
ing Early and Late stages. [43]. In addition, polymor-
phisms in the 17 beta HSD gene (rs 5942 and rs 2389)
were related to a symptom cluster incuding high severity
hot flashes and moderate levels of 5 other symptom
groups (sleep, mood, cognitive, pain symptoms). Moreover
the rs2389 heterozygous allele had a significant positive ef-
fect on estrone and rs2830 homozygous mutant allele had
a significant negative effect on FSH. The rs5942 17 HSD
had no effect on either estrone or FSH (unpublished data).
Women with two CYP19 7r alleles had menarche earl-
ier (11.5 y) than those with one CYP19 7r allele (13.1 y).
Women with two CYP19 11r alleles were 2 years older
at onset of Late stage than those with one CYP19 11r al-
lele (50.7 y vs 48.6 y). Those with two CYP19 7r(−3) alleles
were 2 years older at FMP than those without this allele
(53.9 y vs 51.3 y). Women with the homozygous wild-type
allele for HSDB1 (rs2830) were younger at FMP by 2 years
than those with the heterozygous allele (50.8 y vs 52.9 y).
Women with the heterozygous allele for CYP1B1*2 had a
later age at menarche compared with women with the
homozygous wild type (13 y vs 12.5 y). [44].
Stress and symptoms during the menopausal transition
Although some would contend that the MT is inherently
stressful, factors that influenced the level of perceived
stress among SMWHS participants were inadequate in-
come to meet needs, lower levels of perceived health
status, role burden and current employment [28]. Of
interest was that perceived stress was related to each of
the symptoms studied: hot flashes, depressed mood,
lower sexual desire, difficulty getting to sleep, night-time
awakening, early morning awakening, forgetfulness, diffi-
culty concentrating, but not urinary incontinence symp-
toms. Perceived stress was not related to MT stage nor
to the endocrine assays measured, including E1G, FSH,
cortisol, and the catecholamines.
Symptom clusters associated with the menopausal transition
Analyses of each of the symptoms studied indicated they
were commonly associated with other symptoms, e.g. hot
flashes with sleep problems, depressed mood, pain and cog-
nitive symptoms. The realization that women experienced
multiple, co-occurring symptoms (defined as symptom
clusters) during the MT and early PM led to further study
[45]. Three symptom clusters composed of hot flashes and
five groups of symptoms that had been identified in prior
factor analysis (depressed mood symptoms, sleep disruption
symptoms, tension symptoms, cognitive symptoms, and
pain symptoms) among this community-based cohort [46].
Cluster I was composed of low severity hot flashes with low
severity sleep disruption symptoms, depressed mood symp-
toms, tension symptoms, cognitive symptoms and pain
symptoms (75 %); Cluster II was high severity hot flashes
with a moderate level of the 5 symptom clusters (12 %);
and Cluster III was low severity hot flashes with moderate
severity levels of the 5 symptom clusters (13 %). When each
of the 3 clusters were compared with each other for es-
trone, FSH, testosterone, epinephrine and norepinephrine
significant group differences were between Cluster I (low
hot flash/low symptom clusters) and Cluster III (high hot
flash/moderate symptom clusters), and between Cluster I
and Cluster II (low hot flash/moderate symptom clusters).
Cluster III had lower estrone, higher FSH, lower epineph-
rine and higher norepinephrine than Cluster I and Cluster
II had lower epinephrine levels than Cluster I. Cortisol and
testosterone had no significant group differences among
the 3 clusters [47].
When perceived stress levels were compared among the
3 clusters, Clusters II and III had significantly higher levels
than Cluster I (unpublished data). Finally, polymorphisms
in estrogen synthesis, metabolism, and receptor genes
were tested. Only the 17HSD polymorphisms (rs 5942 and
rs 2389) significantly differentiated Cluster III from Clus-
ter I. None of the polymorphisms differentiated Cluster II
from I or Cluster II from III.
Conclusions and Discussion
Contributions of the SMWHS included:
 Development of a system for staging reproductive
aging with emphasis on the period from the Late
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Reproductive stage through the early PM and
establishment of the validity of the staging system
with the ReSTAGE Collaboration and contributions
to the Staging Reproductive Aging Workshop and
STRAW+ 10 [48];
 Incorporation of the staging system into the study of
endocrine changes during the MT stages and early
PM, including demonstration of changes in estrone,
FSH, testosterone, cortisol, epinephrine and
norepinephrine by MT stages and PM;
 Integration of the staging system into models of
symptoms including hot flashes, sleep disturbances,
depressed mood, pain, cognitive symptoms,
incontinence, and sexual desire;
 Confirmation of effects of the MT stages and early
PM on the following symptoms: hot flashes,
awakening during the night, back pain, and sexual
desire, but not on depressed mood, cognitive
symptoms, incontinence, or joint pain;
 Identification of functional effects of symptoms on
interference with work and relationships, in
particular, effects of depressed mood and difficulty
concentrating on work and depressed mood, anxiety,
difficulty concentrating, and awakening during the
night on relationships;
 Demonstration of effects of gene polymorphisms
CYP 19 11r, 17 beta HSD (rs 2389 and 5942) in
estrogen synthesizing genes on hot flashes as well as
CYP 19 7r, CYP 19 7r(−3), 17 beta HSD (rs 2830)
and estrogen metabolizing gene CYP 1B1*2 on
events related to menarche and the MT; and
 Identification of naturally occurring symptom
clusters and their relationship to endocrine levels
(estrone, FSH), perceived stress, epinephrine,
norepinephrine levels, and 17 beta HSD genotypes.
Results of this study can be generalized to women ex-
periencing the natural menopausal transition and early
postmenopause and who were not using hormone ther-
apy. Limitations of the SMWHS included a predomin-
antly White and well-educated sample, despite efforts to
include Asian American and African American women.
Another limitation was the smaller sample size relative
to larger studies, such as the Study of Women and
Health Across the Nation (SWAN) The limitation of
sample size was compensated in part by the more fre-
quent occasions of measurement, with some measures
obtained several times per year. In addition, SMWHS
was a longitudinal population-based study that enabled
analysis of patterns observed in symptoms over time, up
to 23 years for some participants. Efforts to recruit and
retain a multi-ethnic sample were effective initially, but
with waning retention during the latter years of the
study. In addition, the development and application of
specific criteria for staging the MT and analyzing data to
examine effects of MT stages supported our ability to
distinguish between endocrine factors, stress, and symp-
toms that were influenced by MT stages versus those
who were not [44].
Issues for further study suggested by SMWHS in-
cluded the importance of studying clusters of symptoms
vs single symptoms and the need for interventions tar-
geting multiple symptoms. We have begun examination
of non-pharmacologic therapies that may be effective for
clusters of symptoms vs individual symptoms [49–52].
In the interim, this research is being incorporated in the
clinical education of women’s health care providers [53].
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